









市場行情
/
股票
/
nasdaq-onc
/

Beigene Ltd

ONC

337.890USD

+17.520+5.47%

收盤 01/09, 16:00（美東）報價延遲15分鐘

34.39B總市值

549.39本益比TTM



Beigene Ltd

337.890

+17.520+5.47%

概覽公司財務分析

概覽

公司

財務

分析

關於 Beigene Ltd 公司

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Beigene Ltd簡介



公司代碼ONC

公司名稱Beigene Ltd

上市日期Mar 02, 2016

CEOOyler (John Victor)

員工數量11000

證券類型Depository Receipt

年結日Mar 02

公司地址c/o BeOne Medicines I GmbH

城市BASEL

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Switzerland

郵編4051

電話41616851900

網址https://beonemedicines.com/

公司代碼ONC

上市日期Mar 02, 2016

CEOOyler (John Victor)

Beigene Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Xiaobin Wu, Ph.D.

President, Chief Operating Officer

10.89K

Mr. John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Mr. Michael J. Goller

Non-Executive Independent Director

Mr. Ranjeev Krishana

Lead Non-Executive Independent Director

Mr. Nuoqing (Michael) Yi

Non-Executive Independent Director

Dr. Xiaodong Wang, Ph.D.

Co-Founder, Non-Executive Director

Dr. Eric E. Hedrick, M.D.

Interim Chief Medical Officer, Immuno-Oncology

Mr. Anthony C. (Tony) Hooper

Non-Executive Independent Director

Dr. Corazon Dating (Corsee) Sanders, Ph.D.

Non-Executive Independent Director

Dr. Han (Margaret) Dugan, M.D.

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Xiaobin Wu, Ph.D.

President, Chief Operating Officer

10.89K

Mr. John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Mr. Michael J. Goller

Non-Executive Independent Director

Mr. Ranjeev Krishana

Lead Non-Executive Independent Director

Mr. Nuoqing (Michael) Yi

Non-Executive Independent Director

Dr. Xiaodong Wang, Ph.D.

Co-Founder, Non-Executive Director

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Product

1.37B

97.35%

BRUKINSA

1.04B

73.69%

Tislelizumab

190.62M

13.50%

XGEVA

84.24M

5.97%

BLINCYTO

30.48M

2.16%

其他

-1.31B

-92.66%

地區USD

名稱

營收

佔比

United States

754.86M

53.45%

China

439.88M

31.15%

Europe

166.58M

11.79%

ROW

50.97M

3.61%

業務

地區

業務USD

名稱

營收

佔比

Product

1.37B

97.35%

BRUKINSA

1.04B

73.69%

Tislelizumab

190.62M

13.50%

XGEVA

84.24M

5.97%

BLINCYTO

30.48M

2.16%

其他

-1.31B

-92.66%

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Amgen Inc

17.27%

Baker Bros. Advisors LP

8.02%

PRIMECAP Management Company

4.63%

Capital International Investors

4.60%

Fidelity Management & Research Company LLC

3.43%

其他

62.04%

持股股東

佔比

Amgen Inc

17.27%

Baker Bros. Advisors LP

8.02%

PRIMECAP Management Company

4.63%

Capital International Investors

4.60%

Fidelity Management & Research Company LLC

3.43%

其他

62.04%

股東類型

持股股東

佔比

Investment Advisor

17.53%

Corporation

17.28%

Hedge Fund

8.21%

Investment Advisor/Hedge Fund

3.74%

Sovereign Wealth Fund

0.92%

Research Firm

0.57%

Pension Fund

0.03%

Family Office

0.02%

Family Office

0.02%

其他

51.66%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

564

34.03M

31.03%

-4.53M

2025Q3

565

40.04M

36.51%

-2.11M

2025Q2

558

63.29M

57.54%

+456.15K

2025Q1

585

69.06M

63.84%

+3.36M

2024Q4

575

70.01M

71.38%

+1.65M

2024Q3

603

67.03M

68.90%

-2.04M

2024Q2

601

66.99M

69.35%

-2.19M

2024Q1

621

66.56M

67.86%

-955.35K

2023Q4

626

65.12M

66.49%

-3.71M

2023Q3

632

67.27M

67.88%

-2.05M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Amgen Inc

18.94M

17.27%

Feb 20, 2025

Baker Bros. Advisors LP

8.80M

8.02%

Sep 30, 2025

PRIMECAP Management Company

5.08M

4.63%

-7.82K

-0.15%

Sep 30, 2025

Capital International Investors

5.05M

4.6%

+161.05K

+3.30%

Sep 30, 2025

Fidelity Management & Research Company LLC

3.76M

3.43%

+345.36K

+10.12%

Sep 30, 2025

HHLR Advisors, Ltd.

1.03M

0.94%

Sep 30, 2025

Temasek Holdings Pte. Ltd.

1.01M

0.92%

+999.00

+0.10%

Sep 30, 2025

T. Rowe Price International Ltd

941.86K

0.86%

+9.96K

+1.07%

Sep 30, 2025

T. Rowe Price Associates, Inc.

688.71K

0.63%

+600.48K

+680.59%

Sep 30, 2025

Invus Public Equities Advisors, LLC

492.99K

0.45%

-17.00K

-3.33%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

VanEck Biotech ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.26%

Tema Oncology ETF

2.65%

Global X Aging Population ETF

2.41%

Virtus LifeSci Biotech Products ETF

1.8%

iShares Biotechnology ETF

1.71%

ProShares Ultra Nasdaq Biotechnology

1.02%

Invesco Nasdaq Biotechnology ETF

1.02%

National Security Emerging Markets Index ETF

0.83%

Capital Group Global Equity ETF

0.79%

VanEck Biotech ETF

佔比4.03%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.26%

Tema Oncology ETF

佔比2.65%

Global X Aging Population ETF

佔比2.41%

Virtus LifeSci Biotech Products ETF

佔比1.8%

iShares Biotechnology ETF

佔比1.71%

ProShares Ultra Nasdaq Biotechnology

佔比1.02%

Invesco Nasdaq Biotechnology ETF

佔比1.02%

National Security Emerging Markets Index ETF

佔比0.83%

Capital Group Global Equity ETF

佔比0.79%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Beigene Ltd的前五大股東是誰？



Beigene Ltd的前五大股東如下：
Amgen Inc
持有股份：18.94M
佔總股份比例：17.27%。
Baker Bros. Advisors LP
持有股份：8.80M
佔總股份比例：8.02%。
PRIMECAP Management Company
持有股份：5.08M
佔總股份比例：4.63%。
Capital International Investors
持有股份：5.05M
佔總股份比例：4.60%。
Fidelity Management & Research Company LLC
持有股份：3.76M
佔總股份比例：3.43%。